Curaleaf International has launched its second range of medical cannabis flower products for the UK market.
Europe’s largest vertically integrated cannabis company Curaleaf, formally known as EMMAC Life Science Group, has launched its second range of medical cannabis flower products for the UK market to help improve access and affordability for patients.
The products are being manufactured in the UK and will be an addition to the company’s existing range of flower and oil products.
Affordable, high-quality flower
Curaleaf’s business model which comprises cultivation, extraction, production and distribution, as well as bringing together pioneering science and research, has been designed to ensure high-quality medical cannabis flower is available, accessible and affordable for UK patients.
The products are manufactured at Rokshaw, Curaleaf’s leading UK Specials Manufacturer and the company’s second EU-GMP-certified laboratory, which has manufactured more than 9,000 medical formulations for more than 2,600 NHS and private pharmacies and hospitals across the United Kingdom to date.
CEO of Curaleaf International, Antonio Costanzo, said: “We are very pleased to extend our range of medical cannabis products for the UK market. As a market leader, Curaleaf International is focused on solving the key patient and physician challenges relating to the price, accessibility, and sustainability of medical cannabis products.
“Our vertically integrated supply chain and GMP manufacturing facilities here in the UK allow us to scale rapidly to meet growing patient demand.”
[activecampaign form=31]
